<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00584428</url>
  </required_header>
  <id_info>
    <org_study_id>OU 9206</org_study_id>
    <secondary_id>OU 9206</secondary_id>
    <nct_id>NCT00584428</nct_id>
  </id_info>
  <brief_title>High Dose Chemo With Autologous BMT for Treatment of Metastatic Breast Cancer</brief_title>
  <official_title>High Dose Chemotherapy With Autologous Bone Marrow Transplantation in the Treatment of Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stephenson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the response rate and the response duration of high dose chemotherapy with
      autologous bone marrow transplantation as intensification following induction chemotherapy in
      metastatic breast cancer and to evaluate prospectively the subdivision of patients with
      metastatic breast cancer according to prognostic groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are 2 phases to this study: 1) Induction- which consists of the administration of
      chemotherapeutic drugs- at the end of this phase if the cancer has responded, bone marrow
      will be collected and frozen untol ready for re-infusion; 2) 2nd phase- involves high-doses
      of chemotherapy followed by infusion of bone marrow cells
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1992</start_date>
  <completion_date type="Actual">March 2002</completion_date>
  <primary_completion_date type="Actual">March 2002</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Once 10 patients enrolled in the study ar followed for at least 6 months, a preliminary analysis of the data will occur.</measure>
    <time_frame>Undetermined</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>No secondary outcomes</measure>
    <time_frame>Undetermined</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High-Dose Chemo with Autologous BMT</intervention_name>
    <description>Carboplatin/VP-16/Cytoxan for women 18-59 and Carboplatin/Thiotepa/Cytoxan for women 60-70</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of breast cancer

          -  Age 18-70

          -  Breast cancer at first clinical evidence of metastatic disease

          -  Must have objectively measurable or evaluable disease or be in complete remission

        Exclusion Criteria:

          -  Previous diagnosis of another invasive carcinaom within 10 years (except skin cancer)

          -  CNS involvement
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Selby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2008</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oklahoma</investigator_affiliation>
    <investigator_full_name>Sharon Ross</investigator_full_name>
    <investigator_title>Regulatory</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Cancer Treatment</keyword>
  <keyword>Breast Cancer Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

